CIP
ALXN

Chartwell Investment Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Chartwell Investment Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-9,240
Closed -$1.13M – 450
2016
Q4 		$1.13M Sell
9,240
-95,265
-91% -$11.7M 0.04% 367
2016
Q3 		$12.8M Buy
+104,505
New +$13.5M 0.23% 139
2014
Q4 		– Sell
-50,560
Closed -$8.38M – 382
2014
Q3 		$8.38M Sell
50,560
-58,150
-53% -$9.55M 0.19% 206
2014
Q2 		$17M Buy
108,710
+48,725
+81% +$7.69M 0.35% 109
2014
Q1 		$9.13M Buy
59,985
+920
+2% +$146K 0.19% 194
2013
Q4 		$7.85M Sell
59,065
-77,460
-57% -$9.3M 0.16% 215
2013
Q3 		$15.9M Sell
136,525
-2,425
-2% -$266K 0.36% 110
2013
Q2 		$12.8M Buy
+138,950
New +$13.4M 0.33% 130

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Chartwell Investment Partners's ALXN Position: Q1 2017 in Review

Chartwell Investment Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 9,240 shares — an estimated $1.13M sold.

Chartwell Investment Partners first reported a position in ALXN in Q2 2013 and held it in 8 quarters. The position peaked at $17M in Q2 2014. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Chartwell Investment Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Chartwell Investment Partners sold 9,240 Alexion Pharmaceuticals shares in Q1 2017, an estimated $1.13M.
  • Chartwell Investment Partners first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Chartwell Investment Partners's Alexion Pharmaceuticals position peaked at $17M in Q2 2014.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Chartwell Investment Partners's 13F filing for Q1 2017, filed 12 May 2017.